Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
Why this paper is included
Supporting source evidence:
Risk was higher in those with higher levels of triglycerides and cystatin C (OR ≥ 1.16, p ≤ 2.7 × 10 to 4); lower cholesterol, HDL, and vitamin D (OR ≤ 0.87, p ≤ 9.3 × 10 to 3); in participants taking an ACEi, ARB, oral steroids, or a statin at enrolment (OR ≥ 2.41, p ≤ 1.51 × 10 to 7); and those exposed to higher levels of air pollution at residence (OR ≥ 1.14, p ≤ 4.8 × 10 to 3).
Source: Descriptive statistics and univariate analyses. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Study design awaiting verification.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.
Meta-analysis unclear · Blinding unclear / not reported · Research setting awaiting verification
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
COVID-19 mortality in the UK Biobank cohort: revisiting and evaluating risk factors
Study design awaiting verification · European Journal of Epidemiology · 2021
Original publication title
COVID-19 mortality in the UK Biobank cohort: revisiting and evaluating risk factors
© The Author(s) 2021
Original publication · Publisher record · CC BY 4.0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
What does the authors’ abstract report?
Most studies of severe/fatal COVID-19 risk have used routine/hospitalisation data without detailed pre-morbid characterisation. Using the community-based UK Biobank cohort, we investigate risk factors for COVID-19 mortality in comparison with non-COVID-19 mortality. We investigated demographic, social (education, income, housing, employment), lifestyle (smoking, drinking, body mass index), biological (lipids, cystatin C, vitamin D), medical (comorbidities, medications) and environmental (air pollution) data from UK Biobank (N = 473,550) in relation to 459 COVID-19 and 2626 non-COVID-19 deaths to 21 September 2020. We used univariate, multivariable and penalised regression models.
Age (OR = 2.76 [2.18 to 3.49] per S.D. [8.1 years], p = 2.6 × 10: 17), male sex (OR = 1.47 [1.26 to 1.73], p = 1.3 × 10: 6) and Black versus White ethnicity (OR = 1.21 [1.12 to 1.29], p = 3.0 × 10: 7) were independently associated with and jointly explanatory of (area under receiver operating characteristic curve, AUC = 0.79) increased risk of COVID-19 mortality. In multivariable regression, alongside demographic covariates, being a healthcare worker, current smoker, having cardiovascular disease, hypertension, diabetes, autoimmune disease, and oral steroid use at enrolment were independently associated with COVID-19 mortality.
Penalised regression models selected income, cardiovascular disease, hypertension, diabetes, cystatin C, and oral steroid use as jointly contributing to COVID-19 mortality risk; Black ethnicity, hypertension and oral steroid use contributed to COVID-19 but not non-COVID-19 mortality. Age, male sex and Black ethnicity, as well as comorbidities and oral steroid use at enrolment were associated with increased risk of COVID-19 death. Our results suggest that previously reported associations of COVID-19 mortality with body mass index, low vitamin D, air pollutants, renin: angiotensin: aldosterone system inhibitors may be explained by the aforementioned factors.
Supplementary Information
The online version contains supplementary material available at 10.1007/s10654-021-00722-y.
Authors’ abstract
Most studies of severe/fatal COVID-19 risk have used routine/hospitalisation data without detailed pre-morbid characterisation. Using the community-based UK Biobank cohort, we investigate risk factors for COVID-19 mortality in comparison with non-COVID-19 mortality. We investigated demographic, social (education, income, housing, employment), lifestyle (smoking, drinking, body mass index), biological (lipids, cystatin C, vitamin D), medical (comorbidities, medications) and environmental (air pollution) data from UK Biobank (N = 473,550) in relation to 459 COVID-19 and 2626 non-COVID-19 deaths to 21 September 2020. We used univariate, multivariable and penalised regression models.
Age (OR = 2.76 [2.18 to 3.49] per S.D. [8.1 years], p = 2.6 × 10: 17), male sex (OR = 1.47 [1.26 to 1.73], p = 1.3 × 10: 6) and Black versus White ethnicity (OR = 1.21 [1.12 to 1.29], p = 3.0 × 10: 7) were independently associated with and jointly explanatory of (area under receiver operating characteristic curve, AUC = 0.79) increased risk of COVID-19 mortality. In multivariable regression, alongside demographic covariates, being a healthcare worker, current smoker, having cardiovascular disease, hypertension, diabetes, autoimmune disease, and oral steroid use at enrolment were independently associated with COVID-19 mortality.
Penalised regression models selected income, cardiovascular disease, hypertension, diabetes, cystatin C, and oral steroid use as jointly contributing to COVID-19 mortality risk; Black ethnicity, hypertension and oral steroid use contributed to COVID-19 but not non-COVID-19 mortality. Age, male sex and Black ethnicity, as well as comorbidities and oral steroid use at enrolment were associated with increased risk of COVID-19 death. Our results suggest that previously reported associations of COVID-19 mortality with body mass index, low vitamin D, air pollutants, renin: angiotensin: aldosterone system inhibitors may be explained by the aforementioned factors.
Supplementary Information
The online version contains supplementary material available at 10.1007/s10654-021-00722-y.
Publication and source details
Original title: COVID-19 mortality in the UK Biobank cohort: revisiting and evaluating risk factors
Joshua Elliott; Barbara Bodinier; Matthew Whitaker; Cyrille Delpierre; Roel Vermeulen; Ioanna Tzoulaki; Paul Elliott; Marc Chadeau-Hyam
European Journal of Epidemiology · 2021
© The Author(s) 2021https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.http://dx.doi.org/10.13039/100010661Horizon 2020 Framework Programme874627874739Vermeulen Roel http://dx.doi.org/10.13039/501100000289Cancer Research UK22184Chadeau-Hyam Marc http://dx.doi.org/10.13039/501100000265Medical Research CouncilMR/L01341X/1MR/S019669/1Elliott Paul http://dx.doi.org/10.13039/501100000274British Heart FoundationRE/18/4/34215Elliott PaulRepository JATS snapshot; version as supplied
Source retrieved: 2026-11-11T14:12:13.639798+00:00
DOI: 10.1007/s10654-021-00722-y · PMC7882869